NervGen Pharma develops first-in-class neuroreparative therapeutics that target biological barriers to nervous system repair. Its lead candidate, NVG-291, is a peptide in clinical development for spinal cord injury and other neurotraumatic conditions, supported by technology licensed from Case Western Reserve University.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -9.1 | — |
| Q3 2025 | 0 | — | -4.2 | — |
| Q4 2025 | 0 | — | -26.9 | — |
| Q1 2026 | 0 | — | -1.7 | — |
| Q2 2026 | 0 | — | -29.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Anavex Life Sciences Corp. (AVXL), EDAP TMS S.A. (FOCL), Lexeo Therapeutics, Inc. (LXEO), GoPro, Inc. (GPRO), Ohio Valley Banc Corp. (OVBC), Limoneira Company (LMNR)